A Phase II Study of Sorafenib in Combination With Carboplatin and Docetaxel in the First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Estimate the objective response rate of patients with Stage IIIB/IV NSCLC receiving the combination therapy of Sorafenib and docetaxel/carboplatin
Analysis occurs once last patient completes chemotherapy
Yes
United States: Institutional Review Board
UPCC 12506
NCT00647426
November 2007
December 2012
Name | Location |
---|---|
Abramson Cancer Center Of University of Pennsylvania | Philadelphia, Pennsylvania 19104 |